These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Tichelli A; Passweg J; Wójcik D; Rovó A; Harousseau JL; Masszi T; Zander A; Békássy A; Crawley C; Arat M; Sica S; Lutz P; Socié G; Haematologica; 2008 Aug; 93(8):1203-10. PubMed ID: 18556401 [TBL] [Abstract][Full Text] [Related]
5. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Majhail NS; Parks K; Defor TE; Weisdorf DJ Biol Blood Marrow Transplant; 2006 Oct; 12(10):1038-46. PubMed ID: 17067910 [TBL] [Abstract][Full Text] [Related]
6. Thrombotic complications after haematopoietic stem cell transplantation: early and late effects. Tsakiris DA; Tichelli A Best Pract Res Clin Haematol; 2009 Mar; 22(1):137-45. PubMed ID: 19285280 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of viral infections and hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Shakiba E; Yaghobi R; Ramzi M Exp Clin Transplant; 2011 Dec; 9(6):405-12. PubMed ID: 22142049 [TBL] [Abstract][Full Text] [Related]
8. Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation. Diaz MA; Vicent MG; Prudencio M; Rodriguez F; Marin C; Serrano A; Sevilla J; Casado J; Madero L Haematologica; 2002 Mar; 87(3):292-8. PubMed ID: 11869942 [TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Talmadge JE Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168 [TBL] [Abstract][Full Text] [Related]
10. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991 [TBL] [Abstract][Full Text] [Related]
12. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. Nivison-Smith I; Simpson JM; Dodds AJ; Ma DD; Szer J; Bradstock KF Biol Blood Marrow Transplant; 2009 Oct; 15(10):1323-30. PubMed ID: 19747641 [TBL] [Abstract][Full Text] [Related]
13. Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy. Stoffel N; Rysler C; Buser A; Gratwohl A; Tsakiris DA; Stern M Thromb Haemost; 2010 Jun; 103(6):1228-32. PubMed ID: 20352161 [TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
15. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Uderzo C; Bonanomi S; Busca A; Renoldi M; Ferrari P; Iacobelli M; Morreale G; Lanino E; Annaloro C; Volpe AD; Alessandrino P; Longoni D; Locatelli F; Sangalli H; Rovelli A Transplantation; 2006 Sep; 82(5):638-44. PubMed ID: 16969286 [TBL] [Abstract][Full Text] [Related]
16. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917 [TBL] [Abstract][Full Text] [Related]
17. Late effects after hematopoietic stem cell transplantation--critical issues. Tichelli A; Rovó A; Socié G Curr Probl Dermatol; 2012; 43():132-49. PubMed ID: 22377926 [TBL] [Abstract][Full Text] [Related]
18. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Ando M; Ohashi K; Akiyama H; Sakamaki H; Morito T; Tsuchiya K; Nitta K Nephrol Dial Transplant; 2010 Jan; 25(1):278-82. PubMed ID: 19762604 [TBL] [Abstract][Full Text] [Related]
19. [The clinical characteristic and risk factors for the incidence of invasive fungal infection in patients following allogeneic hematopoietic stem cell transplantation]. Zhang Y; Liu C; Liu QF; Sun J; Fan ZP; Xu D; Jiang QL Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2814-7. PubMed ID: 20137659 [TBL] [Abstract][Full Text] [Related]
20. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. de la Cámara R; Martino R; Granados E; Rodriguez-Salvanés FJ; Rovira M; Cabrera R; López J; Parody R; Sierra J; Fernández-Rañada JM; Carreras E Bone Marrow Transplant; 2000 Aug; 26(3):291-8. PubMed ID: 10967568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]